Author: Eve K. Nichols
Publisher: Theclassics.Us
ISBN: 9781230288727
Category :
Languages : en
Pages : 72
Book Description
This historic book may have numerous typos and missing text. Purchasers can usually download a free scanned copy of the original book (without typos) from the publisher. Not indexed. Not illustrated. 1986-07 edition. Excerpt: ...drug's safety in humans and to begin determination of appropriate dose levels and routes of administration. In phase II trials researchers gather additional information about the most effective way to administer the drug and about possible adverse effects, and they begin to assess its clinical potential. Phase III clinical trials are controlled field studies with larger numbers of patients to develop reasonable estimates of safety and efficacy. Two approaches have been used by scientists in the United States and abroad to accelerate the development of anti-AIDS drugs without bypassing established testing procedures. The first has been to examine the susceptibility of HTLV-III/LAV to drugs originally developed for other purposes. The benefit of this approach is that researchers can bypass toxicity studies in animal models and some of the early stages of clinical trials because they already know how the drug affects human tissues. The second approach has been to develop rapid screening systems for new chemical agents, followed by carefully monitored laboratory and early clinical studies of any promising candidates. In the United States this process has been characterized by ongoing collaborations involving scientists from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, numerous academic medical centers, and the pharmaceutical industry. Constant communication between research scientists and the FDA has accelerated this process even further. Drugs Developed for Other Purposes A variety of existing antiviral drugs have been found to inhibit HTLV-III/LAV in the laboratory, but clinical results have been discouraging. Although some have been shown to reduce viral replication in patients with AIDS, ..
Mobilizing Against Aids; the Unfinished Story of a Virus
Author: Eve K. Nichols
Publisher: Theclassics.Us
ISBN: 9781230288727
Category :
Languages : en
Pages : 72
Book Description
This historic book may have numerous typos and missing text. Purchasers can usually download a free scanned copy of the original book (without typos) from the publisher. Not indexed. Not illustrated. 1986-07 edition. Excerpt: ...drug's safety in humans and to begin determination of appropriate dose levels and routes of administration. In phase II trials researchers gather additional information about the most effective way to administer the drug and about possible adverse effects, and they begin to assess its clinical potential. Phase III clinical trials are controlled field studies with larger numbers of patients to develop reasonable estimates of safety and efficacy. Two approaches have been used by scientists in the United States and abroad to accelerate the development of anti-AIDS drugs without bypassing established testing procedures. The first has been to examine the susceptibility of HTLV-III/LAV to drugs originally developed for other purposes. The benefit of this approach is that researchers can bypass toxicity studies in animal models and some of the early stages of clinical trials because they already know how the drug affects human tissues. The second approach has been to develop rapid screening systems for new chemical agents, followed by carefully monitored laboratory and early clinical studies of any promising candidates. In the United States this process has been characterized by ongoing collaborations involving scientists from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, numerous academic medical centers, and the pharmaceutical industry. Constant communication between research scientists and the FDA has accelerated this process even further. Drugs Developed for Other Purposes A variety of existing antiviral drugs have been found to inhibit HTLV-III/LAV in the laboratory, but clinical results have been discouraging. Although some have been shown to reduce viral replication in patients with AIDS, ..
Publisher: Theclassics.Us
ISBN: 9781230288727
Category :
Languages : en
Pages : 72
Book Description
This historic book may have numerous typos and missing text. Purchasers can usually download a free scanned copy of the original book (without typos) from the publisher. Not indexed. Not illustrated. 1986-07 edition. Excerpt: ...drug's safety in humans and to begin determination of appropriate dose levels and routes of administration. In phase II trials researchers gather additional information about the most effective way to administer the drug and about possible adverse effects, and they begin to assess its clinical potential. Phase III clinical trials are controlled field studies with larger numbers of patients to develop reasonable estimates of safety and efficacy. Two approaches have been used by scientists in the United States and abroad to accelerate the development of anti-AIDS drugs without bypassing established testing procedures. The first has been to examine the susceptibility of HTLV-III/LAV to drugs originally developed for other purposes. The benefit of this approach is that researchers can bypass toxicity studies in animal models and some of the early stages of clinical trials because they already know how the drug affects human tissues. The second approach has been to develop rapid screening systems for new chemical agents, followed by carefully monitored laboratory and early clinical studies of any promising candidates. In the United States this process has been characterized by ongoing collaborations involving scientists from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, numerous academic medical centers, and the pharmaceutical industry. Constant communication between research scientists and the FDA has accelerated this process even further. Drugs Developed for Other Purposes A variety of existing antiviral drugs have been found to inhibit HTLV-III/LAV in the laboratory, but clinical results have been discouraging. Although some have been shown to reduce viral replication in patients with AIDS, ..
Mobilizing Against AIDS. The Unfinished Story of a Virus. (Annual Meeting of The) Inst. of Medicine, (Washington, Oct. 16, 1985). Writer
National Library of Medicine Current Catalog
Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 762
Book Description
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 762
Book Description
Current Catalog
Author: National Library of Medicine (U.S.)
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1676
Book Description
First multi-year cumulation covers six years: 1965-70.
Publisher:
ISBN:
Category : Medicine
Languages : en
Pages : 1676
Book Description
First multi-year cumulation covers six years: 1965-70.
Mobilizing Against AIDS
Author: Eve K. Nichols
Publisher:
ISBN:
Category : Health & Fitness
Languages : en
Pages : 408
Book Description
This new edition, nearly double the size of the first, interprets the results of the latest research on AIDS and possible methods of treatment, explores successful and failed control attempts, and examines special concerns about the impact of the disease on the urban poor in this country. This study is endorsed by the Institute of Medicine/NAS. Paperback edition, $12.95, not seen. Annotation copyrighted by Book News, Inc., Portland, OR
Publisher:
ISBN:
Category : Health & Fitness
Languages : en
Pages : 408
Book Description
This new edition, nearly double the size of the first, interprets the results of the latest research on AIDS and possible methods of treatment, explores successful and failed control attempts, and examines special concerns about the impact of the disease on the urban poor in this country. This study is endorsed by the Institute of Medicine/NAS. Paperback edition, $12.95, not seen. Annotation copyrighted by Book News, Inc., Portland, OR
Public Library Catalog
SAMT
Author:
Publisher:
ISBN:
Category : Electronic journals
Languages : en
Pages : 1254
Book Description
Publisher:
ISBN:
Category : Electronic journals
Languages : en
Pages : 1254
Book Description
News Report
Author: National Research Council (U.S.)
Publisher:
ISBN:
Category : Research
Languages : en
Pages : 392
Book Description
Publisher:
ISBN:
Category : Research
Languages : en
Pages : 392
Book Description
AIDS in Africa and the Caribbean
Author: George Clement Bond
Publisher: Routledge
ISBN: 0429970978
Category : Political Science
Languages : en
Pages : 256
Book Description
This book offers detailed ethnographic studies from Africa and the Caribbean to explain AIDS in a global and comparative third-world context. The essays move beyond medical or epidemiological models, explaining the epidemic in its economic, social, political, and historical contexts.
Publisher: Routledge
ISBN: 0429970978
Category : Political Science
Languages : en
Pages : 256
Book Description
This book offers detailed ethnographic studies from Africa and the Caribbean to explain AIDS in a global and comparative third-world context. The essays move beyond medical or epidemiological models, explaining the epidemic in its economic, social, political, and historical contexts.
Bibliography of Bioethics
Author: LeRoy Walters
Publisher:
ISBN:
Category : Bioethics
Languages : en
Pages : 598
Book Description
Bibliography of works which discuss the ethical aspects of: physician patient relationship, health care, contraception, abortion, population, reproductive technologies, genetic intervention, mental health therapies, human experimentation, artificial and transplated organs are tissues, death and dying, and international dimensions of biology and medicine.
Publisher:
ISBN:
Category : Bioethics
Languages : en
Pages : 598
Book Description
Bibliography of works which discuss the ethical aspects of: physician patient relationship, health care, contraception, abortion, population, reproductive technologies, genetic intervention, mental health therapies, human experimentation, artificial and transplated organs are tissues, death and dying, and international dimensions of biology and medicine.